Omini

CardioCap is the first ever multiplex and multimodal point-of-care (POC) device used for heart failure (HF) therapy management. With just a prick on the patient’s finger, and a drop of blood, healthcare professionals can deduce the severity of the HF patients’ conditions through simultaneous detection of 4 blood biomarkers, namely potassium, sodium, creatinine and NT-proBNP. With the comprehensive data generated by the 4 biomarkers, they can make prompt and informed decisions on the appropriate treatment. By optimising the drug dosage or exploring other treatment options, they can prevent patients entering acute decompensation events or adverse side effects, such as kidney failure. CardioCap is a handheld POC device that works with a drop of blood from the prick of a finger, and is as user-friendly as a glucometer. It performs at the same standard as the gold benchmarks (i.e. The Stratus CS by Siemens, COBAS CARDIAC NTproBNP+ by Roche and standard laboratory testing), but is used after patients are discharged from hospitals. With CardioCap, continuum care for HF patients is made available after hospital discharge, at the patient's home, community care centres, neighbourhood clinics and pharmacies. Re-hospitalisation rate and mortality rate is expected to be reduced by at least 30%. Furthermore, it helps to free up the hospital capacity for other emergency cases that could not be prevented. This mission is aligned with the health inequality gap in the EU, with the World Economic Forum (WEF) stating that ill health accounts for 20% of total healthcare cost. In closing the health inequality gap, the WEF urged for health initiatives such as POC that enable people to receive the health services they need.